Updates are available Correction dated 2023-11-23
Click to view Correction: https://doi.org/10.1186/s12920-023-01742-1
-
Authors
Ying, Shengjie
Heung, Tracy
Thiruvahindrapuram, Bhooma https://orcid.org/0000-0003-1128-008X
Engchuan, Worrawat
Yin, Yue
Blagojevic, Christina
Zhang, Zhaolei https://orcid.org/0000-0002-7303-6472
Hegele, Robert A. https://orcid.org/0000-0003-2861-5325
Yuen, Ryan K. C. https://orcid.org/0000-0001-7273-4968
Bassett, Anne S. https://orcid.org/0000-0002-6183-4493
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (PJT-169161, PJT-148924)
- License Information
-
More Information
Article History
Received: 23 April 2023
Accepted: 25 October 2023
First Online: 8 November 2023
Change Date: 23 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12920-023-01742-1
Declarations
:
: All participants provided written informed consent and the study was approved by the local research ethics boards of hospitals affiliated with the University of Toronto (the Centre for Addiction and Mental Health and University Health Network) where participants were ascertained (e.g., the Dalglish Family 22q Clinic at the Toronto General Hospital), with referrals originating from generalists and specialists. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: Robert A. Hegele reports consulting fees from Acasti, Aegerion, Akcea/Ionis, Amgen, Arrowhead, Boston Heart, HLS Therapeutics, Pfizer, Novartis, Regeneron, Sanofi and Ultragenyx. None of the other authors have any conflicts to report.
